Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2012; Volume 206, Supplement 693
Joint FEPS and Spanish Physiological Society Scientific Congress 2012
9/8/2012-9/11/2012
Santiago de Compostela, Spain


MELATONIN, NITRIC OXIDE SYNTHASES AND PARKINSON'S DISEASE
Abstract number: P64

Lopez Ramirez1 A., Ortiz Garcia1 F, Garcia Santos1 J, Diaz-Casado1 E, Lopez1 LC, Venegas Maldonado1 C, Doerrier1 C, Escames1 G, Acuna Castroviejo1 D

1Instituto de Biotecnologa, Universidad de Granada

Objectives: 

MPTP-mouse model of Parkinson's disease (PD) constitutes a well-known model for studying the participation of oxidative stress, inflammation, and mitochondrial dysfunction in the pathogenesis of PD. The role of iNOS and nNOS on mitochondrial dysfunction under MPTP administration is, however, unclear. Previous reports showed that melatonin (aMT), an important antioxidant and antiinflammatory, exerts neuroprotective properties in different types of neurodegeneration. Here, the participation of iNOS/nNOS in the mitochondrial impairment of the nigrostriatal pathway and aMT treatment, were assayed in iNOS and nNOS deficient mice.

Materials: 

Mice groups: 1) control; 2) MPTP and 3) MPTP + aMT (MPTP, 15 mg/kg; aMT, 10 mg/kg). Complex I activity; NOS activity; mtDNA; OXPHOS expression; respirometry (Oroboros® oxygraph), and behavioral analysis (SMART software) were measured.

Results: 

Complex I activity decreased sharply whereas iNOS activity increased in SN and ST after MPTP. aMT administration counteracted these effects, recovering the control levels. aMT also prevented the mtDNA depletion induced by MPTP. MTPT caused dramatic changes in mitochondrial O2 consumption and bioenergetics, which were counteracted by aMT. MTPT increased the expression of complexes I and II, probably to maintain the O2 flux. Interestingly, aMT administration keeps this increase but in an higher efficient manner as we could prove in the respirometry assays. These biochemical changes were also evident in the behavioral analysis in which the bradykinesia due to MPTP was significantly restored by aMT.

Conclusions: 

Our results suggest that iNOS induction results in an impairment of the mitochondrial function in the SN and ST of MPTP-treated mice. aMT administration counteracted the inflammatory process, restoring the normal mitochondrial function and phenotype of these mice, suggesting an important neuroprotective role for the neurohormone.

Supported in part by grants nordm; PI08-1664 and RD06/0013/0008 (ISCIII), and CTS-101 (Junta de Andalucía).

To cite this abstract, please use the following information:
Acta Physiologica 2012; Volume 206, Supplement 693 :P64

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE